Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:ARQL NASDAQ:HALO NASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$27.39+3.3%$28.13$25.17▼$36.45$4.38B0.531.92 million shs2.14 million shsARQLArQule$20.00$20.00$3.15▼$20.45$2.42B2.495.27 million shsN/AHALOHalozyme Therapeutics$75.85-0.6%$65.95$42.01▼$77.60$8.93B1.191.87 million shs1.15 million shsRGENRepligen$119.75+5.3%$120.34$102.96▼$182.52$6.40B1.07675,297 shs1.36 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-1.67%-6.78%-8.71%-10.92%-4.12%ARQLArQule0.00%0.00%0.00%0.00%0.00%HALOHalozyme Therapeutics-0.74%+0.63%+13.47%+43.72%+22.52%RGENRepligen+0.18%-5.77%-8.53%-6.01%-18.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$27.39+3.3%$28.13$25.17▼$36.45$4.38B0.531.92 million shs2.14 million shsARQLArQule$20.00$20.00$3.15▼$20.45$2.42B2.495.27 million shsN/AHALOHalozyme Therapeutics$75.85-0.6%$65.95$42.01▼$77.60$8.93B1.191.87 million shs1.15 million shsRGENRepligen$119.75+5.3%$120.34$102.96▼$182.52$6.40B1.07675,297 shs1.36 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-1.67%-6.78%-8.71%-10.92%-4.12%ARQLArQule0.00%0.00%0.00%0.00%0.00%HALOHalozyme Therapeutics-0.74%+0.63%+13.47%+43.72%+22.52%RGENRepligen+0.18%-5.77%-8.53%-6.01%-18.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.92Moderate Buy$41.8552.78% UpsideARQLArQule 0.00N/AN/AN/AHALOHalozyme Therapeutics 2.33Hold$67.11-11.52% DownsideRGENRepligen 2.67Moderate Buy$166.6739.18% UpsideCurrent Analyst Ratings BreakdownLatest ARQL, HALO, RGEN, and ALKS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025RGENRepligenJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$145.00 ➝ $135.009/9/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$43.009/9/2025ALKSAlkermesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$34.00 ➝ $35.009/9/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$46.009/3/2025ALKSAlkermesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/3/2025RGENRepligenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$180.009/2/2025RGENRepligenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$205.009/2/2025ALKSAlkermesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$44.009/2/2025HALOHalozyme TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/18/2025HALOHalozyme TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$75.00 ➝ $80.008/7/2025HALOHalozyme TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$60.00 ➝ $63.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B2.90$2.74 per share10.00$9.05 per share3.03ARQLArQule$25.76M93.85N/AN/A$0.72 per share27.78HALOHalozyme Therapeutics$1.02B8.74$4.62 per share16.41$2.86 per share26.52RGENRepligen$634.44M10.62$3.27 per share36.61$35.21 per share3.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0813.1719.991.4923.15%24.86%17.14%10/23/2025 (Estimated)ARQLArQule-$15.48M-$0.16N/AN/AN/A-805.61%-33.10%-26.87%N/AHALOHalozyme Therapeutics$444.09M$4.3717.3612.190.4247.28%150.85%29.19%10/30/2025 (Estimated)RGENRepligen-$25.51M-$0.25N/A50.742.10-2.05%4.61%3.24%11/11/2025 (Estimated)Latest ARQL, HALO, RGEN, and ALKS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025HALOHalozyme Therapeutics$1.23$1.54+$0.31$1.33$282.66 million$325.72 million7/29/2025Q2 2025ALKSAlkermes$0.42$0.52+$0.10$0.52$343.20 million$390.66 million7/29/2025Q2 2025RGENRepligen$0.40$0.37-$0.03$0.26$174.62 million$182.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AARQLArQuleN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.232.85ARQLArQule0.088.278.27HALOHalozyme Therapeutics4.548.367.01RGENRepligen0.268.597.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%ARQLArQule74.63%HALOHalozyme Therapeutics97.79%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%ARQLArQule13.80%HALOHalozyme Therapeutics2.90%RGENRepligen1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800165.08 million157.82 millionOptionableARQLArQule36120.87 millionN/AOptionableHALOHalozyme Therapeutics390116.97 million113.57 millionOptionableRGENRepligen1,77856.26 million55.58 millionOptionableARQL, HALO, RGEN, and ALKS HeadlinesRecent News About These CompaniesRepligen (RGEN) Stock Is Up, What You Need To Know5 hours ago | finance.yahoo.comStrs Ohio Buys Shares of 47,700 Repligen Corporation $RGENSeptember 16 at 3:38 AM | marketbeat.comWhat is Leerink Partnrs' Estimate for Repligen Q4 Earnings?September 16 at 2:11 AM | marketbeat.comQ4 Earnings Estimate for Repligen Issued By Leerink PartnrsSeptember 16 at 2:09 AM | americanbankingnews.comWoodline Partners LP Buys New Shares in Repligen Corporation $RGENSeptember 15 at 4:00 AM | marketbeat.comRepligen (NASDAQ:RGEN) Given New $135.00 Price Target at Jefferies Financial GroupSeptember 14 at 8:14 AM | marketbeat.comOsterweis Capital Management Inc. Has $9.26 Million Position in Repligen Corporation $RGENSeptember 14 at 5:57 AM | marketbeat.comJefferies Financial Group Has Lowered Expectations for Repligen (NASDAQ:RGEN) Stock PriceSeptember 14 at 3:30 AM | americanbankingnews.comUnited Services Automobile Association Acquires New Shares in Repligen Corporation $RGENSeptember 13 at 4:27 AM | marketbeat.comWhy Repligen (RGEN) Stock Is Down TodaySeptember 12, 2025 | msn.comIs There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 29% Undervaluation?September 10, 2025 | uk.finance.yahoo.comRBC Capital Reaffirms Their Buy Rating on Repligen (RGEN)September 10, 2025 | theglobeandmail.comFred Alger Management LLC Boosts Position in Repligen Corporation $RGENSeptember 10, 2025 | marketbeat.comDynamic Technology Lab Private Ltd Raises Stake in Repligen Corporation $RGENSeptember 10, 2025 | marketbeat.comScientech Research LLC Makes New Investment in Repligen Corporation $RGENSeptember 9, 2025 | marketbeat.comRepligen Corporation $RGEN Shares Sold by Polar Asset Management Partners Inc.September 9, 2025 | marketbeat.comSandler Capital Management Sells 8,004 Shares of Repligen Corporation $RGENSeptember 8, 2025 | marketbeat.comCinctive Capital Management LP Sells 59,424 Shares of Repligen Corporation $RGENSeptember 8, 2025 | marketbeat.comGranahan Investment Management LLC Trims Stake in Repligen Corporation $RGENSeptember 7, 2025 | marketbeat.comEFG Asset Management North America Corp. Has $1.65 Million Stake in Repligen Corporation $RGENSeptember 7, 2025 | marketbeat.comAlliancebernstein L.P. Purchases 13,284 Shares of Repligen Corporation $RGENSeptember 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025CrowdStrike at a Crossroads: AI Halo vs. RisksBy Chris Markoch | August 28, 2025Alphabet’s Resurgence: It's Now a Clear Market LeaderBy Ryan Hasson | September 2, 2025ARQL, HALO, RGEN, and ALKS Company DescriptionsAlkermes NASDAQ:ALKS$27.39 +0.87 (+3.28%) Closing price 04:00 PM EasternExtended Trading$27.40 +0.00 (+0.02%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.ArQule NASDAQ:ARQLArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.Halozyme Therapeutics NASDAQ:HALO$75.85 -0.48 (-0.63%) Closing price 04:00 PM EasternExtended Trading$75.70 -0.15 (-0.20%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Repligen NASDAQ:RGEN$119.75 +6.01 (+5.28%) Closing price 04:00 PM EasternExtended Trading$119.80 +0.05 (+0.04%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
